期刊文献+
共找到870篇文章
< 1 2 44 >
每页显示 20 50 100
Response of levetiracetam in neonatal seizures 被引量:1
1
作者 Maggie Lo-Yee Yau Eva Lai-Wah Fung Pak Cheung Ng 《World Journal of Clinical Pediatrics》 2015年第3期45-49,共5页
AIM: To review the clinical response to levetiracetam(LEV) in neonatal seizure management in intensive care unit.METHODS: Medical records of neonates who received LEV from January 2009 to August 2014 were reviewed. Th... AIM: To review the clinical response to levetiracetam(LEV) in neonatal seizure management in intensive care unit.METHODS: Medical records of neonates who received LEV from January 2009 to August 2014 were reviewed. Their demographic data, clinical characteristics, etiology, seizures, electroencephalograms, response to treatment and outcome were noted. Literature review of use of LEV in neonates were also performed via Pub Med and EMBASE with keywords- "neonates", "seizures", "epilepsy" and "LEV" up to Sep 2014 and retrieved the publications. The response rate to LEV was compared.RESULTS: Twelve neonates were identified during the study period. All patients received phenobarbitone loading prior to consideration of LEV. Seven(58%) and nine(75%) achieved seizure freedom 24 h and 72 h after LEV was added, both clinically and electrographically. No serious adverse effects were associated with LEV use. From the literature, there are total 144 neonates reported to have used LEV. The overall results suggested that LEV could control up to 90% of neonatal seizures.CONCLUSION: LEV was found to be relatively safe and efficacious in treating neonatal seizures, but might not work well in the most severe hypoxic ischemic encephalopathy. 展开更多
关键词 levetiracetam PHENOBARBITONE NEONATES Seizures
下载PDF
Acute liver failure following levetiracetam therapy for seizure prophylaxis in traumatic brain injury 被引量:1
2
作者 Aasim Ali Syed Christopher D. Adams 《Case Reports in Clinical Medicine》 2012年第2期42-45,共4页
This case report investigates an uncommon occurrence of drug induced acute liver injury directly associated with the administration of levetiracetam in a patient following traumatic brain injury.
关键词 levetiracetam Liver Failure SEIZURE PROPHYLAXIS TRAUMATIC Brain Injury ADVERSE Drug Reaction
下载PDF
胆碱能激动剂 抗癫痫药左乙拉西坦(Levetiracetam) 被引量:2
3
作者 李晓东 《国外医药(合成药.生化药.制剂分册)》 2001年第2期125-125,共1页
关键词 抗癫痫药 左乙拉西坦 levetiracetam 适应证 药理临床评价 不良反应
下载PDF
Levetiracetam induces tyrosine kinase receptor B expression in SH-SY5Y cells
4
作者 Danrong Lei Shengfu Li Xiaoyi Zou 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第14期1082-1085,共4页
Tyrosine kinase receptor B (TrkB) plays an important role in long-term potentiation and memory formation.The present study used all-trans retinoic acid to induce TrkB expression in SH-SY5Y cells,and observed the eff... Tyrosine kinase receptor B (TrkB) plays an important role in long-term potentiation and memory formation.The present study used all-trans retinoic acid to induce TrkB expression in SH-SY5Y cells,and observed the effects of levetiracetam (LEV) on TrkB expression.Following exposure to 10,50,and 100 μg/mL LEV,the number of TrkB-positive cells,and average absorbance value were increased.Results demonstrated that LEV can induce TrkB expression in SH-SY5Y cells. 展开更多
关键词 levetiracetam tyrosine kinase receptor B brain-derived neurotrophic factor COGNITION SH-SY5Y cells neural regeneration
下载PDF
Levetiracetam-Associated Acute Kidney Injury and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome
5
作者 Mathieu Leblanc Martin Plaisance 《Open Journal of Nephrology》 2014年第4期152-155,共4页
DRESS syndrome is a severe drug induced reaction. Acute kidney injury (AKI) is sometimes present in the form of an acute interstitial nephritis. We present the case of a 75-year-old man with glioblastoma who developed... DRESS syndrome is a severe drug induced reaction. Acute kidney injury (AKI) is sometimes present in the form of an acute interstitial nephritis. We present the case of a 75-year-old man with glioblastoma who developed a DRESS two months after starting levetiracetam and a few days after stopping dexamethasone. His skin and kidneys improved after removing levetiracetam and introducing again corticosteroids. DRESS has been reported more frequently with other antiepileptics, rarely with levetiracetam. Clinicians should add this drug to the list of potential causes of AKI. 展开更多
关键词 Acute KIDNEY Injury DRESS SYNDROME HSV-1 levetiracetam
下载PDF
抗癫痫药Levetiracetam
6
作者 范鸣 《药学进展》 CAS 2000年第4期250-251,共2页
关键词 抗癫痫药 levetiracetam 药理作用 临床研究
下载PDF
Levetiracetam用于幼儿期重症肌阵挛性癫痫的开放试验
7
作者 张忠 《国际内科学杂志》 CAS 2008年第8期F0003-F0003,共1页
关键词 levetiracetam 肌阵挛性癫痫 开放试验 重症肌 幼儿期 给药治疗 安全性
下载PDF
Levetiracetam对肝移植后癫痫发作的作用
8
作者 肖佩荣 《国际内科学杂志》 CAS 2007年第2期F0003-F0003,共1页
关键词 levetiracetam 原位肝移植 癫痫发作 移植后 低剂量免疫抑制剂 细胞色素P450系统 细胞色素P450酶 药物短程治疗
下载PDF
Influence of adjuvant levetiracetam therapy on serum nerve cytokines and apoptosis molecules in patients with refractory partial epileptic seizure
9
作者 Xiang-Hong Tan Zhi-Bin Song +2 位作者 Hui Wang Qin Wang Jian-Li He 《Journal of Hainan Medical University》 2017年第11期145-149,共5页
Objective:To study the influence of adjuvant levetiracetam therapy on serum nerve cytokines and apoptosis molecules in patients with refractory partial epileptic seizure.Methods: A total of 92 patients with refractory... Objective:To study the influence of adjuvant levetiracetam therapy on serum nerve cytokines and apoptosis molecules in patients with refractory partial epileptic seizure.Methods: A total of 92 patients with refractory partial epileptic seizure treated in our hospital between July 2012 and January 2016 were divided into control group (n=46) and observation group (n=46) according to random number table. Patients in the control group were treated with routine treatment, those in observation group were treated with routine treatment plus adjuvant levetiracetam therapy, and the treatment lasted for 20 weeks. Serum contents of nerve cytokines and apoptosis molecules were compared between two groups before and after treatment.Results:Before treatment, differences in serum levels of nerve injury indexes, nerve protection indexes, monoamine neurotransmitters and apoptosis molecules were not statistically significant between two groups of patients. After treatment, serum contents of nerve injury indexes S-100β, GFAP, NSE and MBP in both groups were significantly lower than those before treatment, contents of nerve protection indexes BDNF and IGF-1 were significantly higher than those before treatment, contents of monoamine neurotransmitters DA, 5-HT and NE were significantly higher than those before treatment, contents of apoptosis molecules Bcl-2, Fas and FasL were significantly lower than those before treatment, and the changes in contents of above indexes in observation group were larger than those in control group.Conclusion:The adjunctive therapy of levetiracetam can reduce the nerve injury in patients with refractory partial epileptic seizure and exert active cerebral protective effect. 展开更多
关键词 REFRACTORY epilepsy levetiracetam NERVE CYTOKINE APOPTOSIS molecule
下载PDF
Acute Kidney Injury with Levetiracetam in Patient with Epilepsy: A Case Report
10
作者 Khalid Al-Quliti Rakan Maher Alhujeily 《Case Reports in Clinical Medicine》 2022年第3期48-54,共7页
Epilepsy is a common neurological disorder in neurology clinic. Levetiracetam is considered as one of common antiepileptic drugs used to manage epilepsy with good efficacy and tolerability profile. It is renally excre... Epilepsy is a common neurological disorder in neurology clinic. Levetiracetam is considered as one of common antiepileptic drugs used to manage epilepsy with good efficacy and tolerability profile. It is renally excreted and not depending on the cytochrome p450. It has adverse effects reported as somnolence, headaches, dizziness, depression and anxiety. Also, it was reported that levetiracetam can cause Acute kidney injury (AKI), renal profile disturbance, that may be related to its way of excretion and possible nephrotoxicity especially with high loading dose. We are reporting a young female patient with epilepsy presented to hospital with status epileptcus and started on loading dose of levetiracetam 3 grams and then maintenance dose of 1 gram twice daily seizure were controlled but she developed acute kidney injury that improved after discontinue leveriracetam and medical management without renal dialysis and discharged home in stable condition. Physician and health care providers should be aware of such rare adverse reaction and available management options for better patient care and outcome. 展开更多
关键词 Acute Kidney Injury EPILEPSY levetiracetam
下载PDF
Levetiracetam的口服溶液获准
11
作者 刘敏 《国外药讯》 2003年第9期30-30,共1页
关键词 levetiracetam 口服溶液 美国 FDA 左乙拉西坦 Keppra片剂
下载PDF
Effects of sodium valproate combined with levetiracetam in treatment of children epilepsy and its influences on serum S-100βand high mobility group box-1
12
作者 Huimin Li Jinli Hao +1 位作者 Hua Chen Yong Meng 《Discussion of Clinical Cases》 2020年第1期12-18,共7页
Objective:To explore the effects of sodium valproate combined with levetiracetam in the treatment of children epilepsy,and its influences on serum S-100βand high mobility group box-1(HMGB-1)in children with epilepsy.... Objective:To explore the effects of sodium valproate combined with levetiracetam in the treatment of children epilepsy,and its influences on serum S-100βand high mobility group box-1(HMGB-1)in children with epilepsy.Methods:A total of 160 children who were diagnosed as epilepsy in Baogang Hospital of Inner Mongolia from July 2016 to October 2018 were selected as research objects.They were randomly divided into the study group(n=80)and the control group(n=80)by the random number table method,i.e.,they were treated with sodium valproate combined with levetiracetam and sodium valproate alone,respectively.After 16 weeks of treatment,the effective rates of epileptic seizure treatment and the improvement of epileptiform discharge were evaluated,and chi-square test was used for statistical comparison.The related indicators,including serum tumor necrosis factor-(TNF-α),hypersensitive C-reactive protein(hs-CRP),homocysteine(Hcy),haematocrit(HCT),erythrocyte sedimentation rate(ESR),serum S-100βand HMGB-1,were measured before and after treatment.Paired t-test was used for the comparison in the above indicators within a group before and after treatment;group t-test was used for the comparison between two groups.Chi-square test was used for the comparison in the rate of adverse reactions during treatment between two groups.The study was approved by Ethics Committee of Baogang Hospital(Approval No.:BG201606073),and all children’s guardians were required to sign informed consent forms for clinical study.There were no statistically significant differences between two groups in general clinical data(p>0.05),such as sex constituent ratio,age,the course of disease,the frequency of epileptic seizure per year before treatment,the incidence of epileptiform discharge before treatment and the constituent ratio of types of epileptic seizure,etc.Results:1)After treatment,the effective rates of epileptic seizure treatment and the improvement of epileptiform discharge in the study group were 92.5%(74/80)and 85.0%(68/80)respectively,which were both significantly higher than those in the control group[68.8%(55/80)and 58.8%(47/80)],and the differences were statistically significant(Х^(2)=14.444,13.635;p<0.001).2)In the study group,the levels of serum TNF-α,hs-CRP and Hcy,as well as HCT and ESR after treatment were(53.1±14.0)pg/ml,(5.0±2.5)mg/L,(12.5±3.1)μmol/L,(38.1±5.1)%and(3.0±0.5)mm/h respectively,which were all significantly lower than those[(107.9±17.8)pg/ml,(10.1±2.5)mg/L,(42.2±5.8)μmol/L,(45.3±4.5)%and(5.2±0.6)mm/h]before treatment,and all the differences were statistically significant(t=21.644,12.902,40.393,9.468,25.194;p<0.001).In the control group,the levels of serum TNF-α,hs-CRP and Hcy,as well as HCT and ESR after treatment were(60.6±17.8)pg/ml,(8.2±2.2)mg/L,(15.2±3.1)μmol/L,(40.2±3.4)%and(4.5±0.6)mm/h respectively,which were all significantly lower than those[(112.4±14.3)pg/ml,(9.3±3.8)mg/L,(41.1±2.8)μmol/L,(44.6±5.5)%and(5.4±0.8)mm/h]before treatment,and all the differences were statistically significant(t=20.292,2.241,55.456,3.320,8.050;p<0.05).After treatment,the above indicators in the study group were all significantly lower than those in the control group,and all the differences were statistically significant(t=2.962,8.595,5.508,3.064,17.178;p<0.05).3)In the study group,the levels of serum S-100βand HMGB-1 after treatment were(0.65±0.38)μg/L and(5.3±2.4)μg/L respectively,which were significantly lower than those[(0.91±0.32)μg/L and(8.1±2.0)μg/L]before treatment,and the differences were statistically significant(t=4.681,8.020;p<0.001).In the control group,the levels of serum S-100βand HMGB-1 after treatment were(0.78±0.27)μg/L and(6.4±2.2)μg/L respectively,which were significantly lower than those[(0.88±0.25)μg/L and(7.9±1.7)μg/L]before treatment,and the differences were statistically significant(t=2.431,p=.016;t=4.826,p<0.001).After treatment,the levels of serum S-100βand HMGB-1 in the study group were significantly lower than those in the control group,and the differences were statistically significant(t=2.495,p=.014;t=2.840,p=.005).4)There was no significant difference between two groups in the rate of adverse reactions,such as nausea,vomiting,poor appetite,dizziness,drowsiness,hepatic and renal injury during treatment(p>0.05).Conclusions:The efficacy of sodium valproate combined with levetiracetam is obviously better than that of sodium valproate alone in the treatment of children epilepsy.The children patients’serum S-100βand HMGB-1 are more significantly reduced,resulting in a lower rate of adverse reactions,which has a certain clinical value. 展开更多
关键词 EPILEPSY Sodium valproate levetiracetam S-100 HMGB-1 protein Tumor necrosis factor- HAEMATOCRIT CHILDREN
下载PDF
Levetiracetam治疗部分原发性癫痫发作的辅助作用
13
《国外新药介绍》 2002年第1期10-12,共3页
关键词 levetiracetam 原发性癫痫 辅助作用 药理学 药物动力学 疗效
下载PDF
抗惊厥药Levetiracetam
14
作者 公玉舜 《山东医药工业》 1994年第4期44-44,8,共2页
[合成]该化合物可通过用(S)-2-氨基丁酰胺(Ⅰ)与4-溴丁酸乙酯(Ⅱ)在三乙胺存在下于甲苯中反应生成(S)-4-[1-(氨基甲酰基)丙胺]丁酸乙酯(Ⅲ),再用2-羟基吡啶在甲苯中环合得到。化合物(Ⅰ)也能与4-氯丁酰氯(Ⅳ)直接在溴化四丁铵存在下于... [合成]该化合物可通过用(S)-2-氨基丁酰胺(Ⅰ)与4-溴丁酸乙酯(Ⅱ)在三乙胺存在下于甲苯中反应生成(S)-4-[1-(氨基甲酰基)丙胺]丁酸乙酯(Ⅲ),再用2-羟基吡啶在甲苯中环合得到。化合物(Ⅰ)也能与4-氯丁酰氯(Ⅳ)直接在溴化四丁铵存在下于二氯甲烷中缩合, 展开更多
关键词 抗惊厥药 levetiracetam
下载PDF
Development of SV2A Ligands for Epilepsy Treatment:A Review of Levetiracetam,Brivaracetam,and Padsevonil
15
作者 Peng-Peng Wu Bi-Rong Cao +1 位作者 Fu-Yun Tian Zhao-Bing Gao 《Neuroscience Bulletin》 SCIE CAS CSCD 2024年第5期594-608,共15页
Epilepsy is a common neurological disorder that is primarily treated with antiseizure medications(ASMs).Although dozens of ASMs are available in the clinic,approximately 30%of epileptic patients have medically refract... Epilepsy is a common neurological disorder that is primarily treated with antiseizure medications(ASMs).Although dozens of ASMs are available in the clinic,approximately 30%of epileptic patients have medically refractory seizures;other limitations in most traditional ASMs include poor tolerability and drug-drug interactions.Therefore,there is an urgent need to develop alternative ASMs.Levetiracetam(LEV)is a first-line ASM that is well tolerated,has promising efficacy,and has little drug-drug interaction.Although it is widely accepted that LEV acts through a unique therapeutic target synaptic vesicle protein(SV)2A,the molecular basis of its action remains unknown.Even so,the next-generation SV2A ligands against epilepsy based on the structure of LEV have achieved clinical success.This review highlights the research and development(R&D)process of LEV and its analogs,brivaracetam and padsevonil,to provide ideas and experience for the R&D of novel ASMs. 展开更多
关键词 levetiracetam EPILEPSY Antiseizure medications Synaptic vesicle protein 2A BRIVARACETAM Padsevonil
原文传递
Antimyoclonic Effect of Levetiracetam and Clonazepam Combined Treatment on Myoclonic Epilepsy with Ragged-Red Fiber Syndrome with m.8344A〉G Mutation 被引量:7
16
作者 Li-Jun Su Yu-Liang Wang +6 位作者 Tao Han Shan Qiao Ke-Jun Zang Huai-Kuan Wu Yong-Xin Su Ling-Ling Liu Xue-Wu Liu 《Chinese Medical Journal》 SCIE CAS CSCD 2018年第20期2433-2438,共6页
Background: Treatment of myoclonic seizures in myoclonic epilepsy with ragged-red fibers (MERRFs) has been empirical and ineffective. Guideline on this disease is not available. Additional trials must be conducted ... Background: Treatment of myoclonic seizures in myoclonic epilepsy with ragged-red fibers (MERRFs) has been empirical and ineffective. Guideline on this disease is not available. Additional trials must be conducted to find more suitable treatments for it. In this study, the antimyoclonic effects ofmonotherapies, including levetiracetam (LEV), clonazepam (CZP), valproic acid (VPA), and topiramate (TPM) compared to combination therapy group with LEV and CZP on MERRF, were evaluated to find a more advantageous approach on the treatment of myoclonic seizures. Methods: Treatments of myoclonic seizures with VPA, LEV, CZP, and TPM were reported as monotherapies in 17 MERRF patients from Qilu Hospital between 2003 and 2016, who were diagnosed through clinical data and genetic testing. After 1-4 months oflbllow-up (mean: 82.9 ± 28.1 days), 12 patients that exhibited poor responses to monotherapy were given a combined treatment consisting of LEV and CZP subsequently. The lbllow-up period was 4-144 months (mean: 66.3 ± 45.3 months), the effective rates of monotherapy group (17 patients) and combination therapy group (12 patients) were analyzed by Chi-square test. Results: The m.8344 A〉G mutation was detected in all patients. There were lbur patients with partial response (4/17, two in the CZP group and two in the LEV group), ten patients with stable disease (10/17, six in the CZP group, three in the LEV group, and one in the TPM group), and three patients with progressive disease (3/18, two in the VPA group and one in the TPM group). Twelve of the patients with LEV combined with CZP showed a positive effect and good tolerance (12/12), eight of them demonstrated improved cognition and coordination. There was a significant difference between the monotherapy group and combination therapy gToup in the efficacy ofantimyoclonic seizures (χ^2 = 13.7, P 〈 0.001 ). Conclusions: LEV in combination with CZP is an efficient and sale treatment for myoclonic seizures in patients with this disease exhibiting the m.8344A〉G mutation. 展开更多
关键词 CLONAZEPAM levetiracetam Myoclonic Epilepsy with Ragged-Red Fibers Myoclonic Seizures
原文传递
Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study 被引量:5
17
作者 Zhe Zhang Dan-Hua Zhao +5 位作者 Xu-Tong Zhao Xiao Zhang Hui Xiong Xin-Hua Bao Yun Yuan Zhao-Xia Wang 《Chinese Medical Journal》 SCIE CAS CSCD 2019年第3期269-274,共6页
Background:Studies on the relationship between antiepileptic drug (AED) administration and clinical outcomes in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) remain s... Background:Studies on the relationship between antiepileptic drug (AED) administration and clinical outcomes in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) remain scarce. Levetiracetam (LEV) is an AED that is neuroprotective in various neurologic disorders. This study aimed to determine the impact of LEV on the outcome of MELAS.Methods:A retrospective, single-center study was performed based on a large cohort of patients with MELAS with a history of seizures (n=102). Decisions on antiepileptic therapies were made empirically. Patients were followed up for 1 to 8 years (median, 4 years) and divided into 2 groups based on whether LEV was administered (LEV or non-LEV). The modified Rankin scale (mRS) scores and mortality risks were analyzed in all patients.Results:LEV, carbamazepine, benzodiazepines, topiramate, oxcarbazepine, valproate, and lamotrigine were administered in 48, 37, 18, 13, 11, 9, and 9 patients, singly or in combination, respectively. The mean mRS score of the LEV group (n=48) was lower than that of the non-LEV group (n=54;mean±standard deviation, 2.79±1.47 vs. 3.83±1.93, P=0.006) up to the end of the study. Nevertheless, there was no difference in the proportion of subjects without disability (mRS ranging 0-1) between the groups (P=0.37). The multivariate regressions revealed that LEV treatment was associated with lower mRS scores (odds ratio 0.32, 95% confidence interval [CI] 0.15-0.68, P=0.003) and mortality rates (hazard ratio 0.24, 95% CI 0.08-0.74, P=0.013). There was a significant difference in the Kaplan-Meier survival curves between the groups (χ^2=4.29, P=0.04).Conclusions:The LEV administration is associated with lower mortality in patients with MELAS in this retrospective study. Further laboratory research and prospective cohort studies are needed to confirm whether LEV has neuroprotective effects on patients with mitochondrial diseases. 展开更多
关键词 Syndrome Seizures EPILEPSY ANTICONVULSANTS levetiracetam Survival analysis
原文传递
Beneficiality of combined levetiracetam, clonazepam for myoclonus in MERRF requires further confirmation 被引量:3
18
作者 Josef Finsterer 《Chinese Medical Journal》 SCIE CAS CSCD 2019年第5期622-623,共2页
To the Editor: With interest, we read the article by Su et al[1] about the antiepileptic drug (AED) treatment of 17 patients with genetically confirmed myoclonic epilepsy with ragged-red fibers (MERRF) syndrome. It wa... To the Editor: With interest, we read the article by Su et al[1] about the antiepileptic drug (AED) treatment of 17 patients with genetically confirmed myoclonic epilepsy with ragged-red fibers (MERRF) syndrome. It was found that monotherapy with either levetiracetam (LEV), clonazepam (CZP), valproic acid (VPA). 展开更多
关键词 COMBINED levetiracetam MYOCLONUS MERRF
原文传递
Pharmacokinetics, safety and bioequivalence of intravenous and oral formulations of the antiepileptic drug levetiracetam in healthy Chinese volunteers 被引量:2
19
作者 Lanlan Hu Juan Zhou +2 位作者 Huan Zou Yue Zhang Jianlin Tang 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2018年第11期777-786,共10页
The intravenous formulation of levetiracetam (LEV)has been available in clinical practice worldwide for several years,but not in China.In the present study,we aimed to evaluate the bioequivalence of intravenous and or... The intravenous formulation of levetiracetam (LEV)has been available in clinical practice worldwide for several years,but not in China.In the present study,we aimed to evaluate the bioequivalence of intravenous and oral LEV (tablet), an antiepileptic drug,in healthy Chinese volunteers.Two randomized,single-dose (1500mg),open-label,2-period crossover trials were conducted as follows:study A,15-min infusion;study B,45-min infusion.A total of 22healthy men participated in study A,and 24healthy men and woman were enrolled in study B.In study A,blood samples were collected after termination of each treatment.In study B,samples were collected after oral or after the start of the intravenous administration.Safety and the ratio of intravenous/oral LEV for AUC 0-t and Cmax were evaluated.The 90% confidence intervals of Cmax and AUC0-t ratios for LEV 1500-mg tablets versus 15-min intravenous administration were outside the bioequivalence limits (80.00%-125.00%). For LEV 45-min intravenous administration,bioequivalence versus 1500-mg tablets was within the range for Cmax and AUC 0-t. The most frequently adverse event (AE)was somnolence.A total of eight subjects experienced nine mild AEs in study A, and 19subjects experienced 29mild AEs in study B.Intravenous infusions (15 and 45 min)of 1500-mg LEV were as well tolerated as the oral tablet.Bioequivalence was demonstrated by 45-min infusions.Therefore,direct conversion from oral to intravenous LEV 1500 mg (45-min infusion),or vice versa,was possible. 展开更多
关键词 levetiracetam EPILEPSY Intravenous formulation BIOEQUIVALENCE Safety and tolerability
原文传递
Effect of levetiracetam and valproate on late‑onset post‑traumatic seizures
20
作者 Yanli Wang Yiqi Wang +4 位作者 Huifang Wang Xiaoping Du Jie Miao James X.Tao Meizhen Sun 《Acta Epileptologica》 2023年第2期86-89,共4页
Background To compare the preventive effects of levetiracetam and valproate on late-onset post-traumatic seizures in patients with traumatic brain injury(TBI).Methods A total of 95 patients with TBI were recruited fro... Background To compare the preventive effects of levetiracetam and valproate on late-onset post-traumatic seizures in patients with traumatic brain injury(TBI).Methods A total of 95 patients with TBI were recruited from 2017 to 2020.They were randomized into three groups:levetiracetam(LEV)group(n=30)receiving LEV treatment(500 mg,bid,po);valproate group(n=32)receiving sodium valproate(500 mg/d,once daily,po);and control group(n=33)receiving no anti-seizure medication.LEV and valproate were given to corresponding groups within seven days after TBI,and the administration lasted for one month.The incidence of epilepsy and adverse events were evaluated at 7 days and 12 months post-TBI.Results The cumulative incidences of late post-traumatic seizures at the 12-month follow-up in the LEV,valproate,and control groups were 3.33%,12.50%and 15.63%,respectively.The cumulative incidence of late post-traumatic seizures in the LEV group was significantly lower than those in the valproate and control groups(P<0.05).The cumulative incidence of late post-traumatic seizure in the valproate group was not significantly different from that in the control group(P>0.05).Conclusions LEV can reduce the cumulative incidence of late post-traumatic seizures,whereas valproate can not. 展开更多
关键词 levetiracetam Valproate Post-traumatic seizure
原文传递
上一页 1 2 44 下一页 到第
使用帮助 返回顶部